000087558 001__ 87558
000087558 005__ 20220120225833.0
000087558 0247_ $$2doi$$a10.1080/14737167.2019.1567338
000087558 0248_ $$2sideral$$a110705
000087558 037__ $$aART-2019-110705
000087558 041__ $$aeng
000087558 100__ $$0(orcid)0000-0002-7194-8275$$aMalo, S.$$uUniversidad de Zaragoza
000087558 245__ $$aPrescribing pattern of antihypertensive drugs in two European cohorts: a population-based database study
000087558 260__ $$c2019
000087558 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087558 5203_ $$aBackground: Antihypertensive drugs play a crucial role in reducing cardiovascular morbidity and mortality. Variability in prescribing patterns constitutes a major challenge for current healthcare systems. This study aimed to compare patterns of use of antihypertensives in general practice in two southern European populations.
Methods: Observational study. Data on antihypertensive drugs consumption in primary care setting (2016) were obtained from pharmacy refill records in Campania (Italy) and Aragon (Spain). Prescribing rates and the number of defined daily doses [DDD/1, 000 inhabitants/day (DID)] were calculated, and the Drug Utilization 90% (DU90%) approach used to reveal differences in prescribing patterns in both regions.
Results: Antihypertensive prescribing rates in Campania and Aragon were 250.8 (95%CI: 250.2–251.3) and 201.7 (95%CI: 200.9–202.5) users/1, 000 inhabitants/year. Overall consumption was of 310.1 and 256.8 DID, respectively. Spanish users, especially women and the elderly, consumed a greater volume of diuretics. Conversely, other therapeutic subgroups were more consumed in Campania. However, the most prescribed subgroups accounted for comparable proportions of the total consumption in each region.
Conclusions: Both prescribing rates and intensity of antihypertensive use were higher in Campania. Pharmacy refill records in cross-country comparisons allow to know the factors influencing variability in prescribing habits with a view to improving prescribing quality.
000087558 536__ $$9info:eu-repo/grantAgreement/ES/DGA-GRISSA/B09-17R
000087558 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000087558 590__ $$a2.032$$b2019
000087558 591__ $$aHEALTH POLICY & SERVICES$$b38 / 87 = 0.437$$c2019$$dQ2$$eT2
000087558 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b54 / 102 = 0.529$$c2019$$dQ3$$eT2
000087558 591__ $$aPHARMACOLOGY & PHARMACY$$b194 / 270 = 0.719$$c2019$$dQ3$$eT3
000087558 592__ $$a0.784$$b2019
000087558 593__ $$aHealth Policy$$c2019$$dQ2
000087558 593__ $$aPharmacology (medical)$$c2019$$dQ2
000087558 593__ $$aMedicine (miscellaneous)$$c2019$$dQ2
000087558 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000087558 700__ $$0(orcid)0000-0002-6671-5661$$aRabanaque, M.J.$$uUniversidad de Zaragoza
000087558 700__ $$aOrlando, V.
000087558 700__ $$aLimongelli, G.
000087558 700__ $$0(orcid)0000-0002-2712-6709$$aFeja, C.
000087558 700__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, I.$$uUniversidad de Zaragoza
000087558 700__ $$0(orcid)0000-0001-7587-9716$$aLallana, M.J.
000087558 700__ $$aRusso, V.
000087558 700__ $$aMenditto, E.
000087558 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000087558 773__ $$g19, 4 (2019), 463-471$$pExpert Review of Pharmacoeconomics and Outcomes Research$$tExpert Review of Pharmacoeconomics and Outcomes Research$$x1473-7167
000087558 8564_ $$s446474$$uhttps://zaguan.unizar.es/record/87558/files/texto_completo.pdf$$yPostprint
000087558 8564_ $$s62410$$uhttps://zaguan.unizar.es/record/87558/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000087558 909CO $$ooai:zaguan.unizar.es:87558$$particulos$$pdriver
000087558 951__ $$a2022-01-20-22:56:07
000087558 980__ $$aARTICLE